Please provide your email address to receive an email when new articles are posted on . “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses ...

Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...

Results for EMPEROR-Reduced have been highly anticipated, as they are expected to set off a new round of competition in the drug class, which was first developed to treat type 2 diabetes.

In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction. Empagliflozin reduces the risk for heart ...

Given the substantial economic burden of heart failure (HF), particularly HF with reduced ejection fraction (HFrEF), understanding its underlying neurohormonal mechanisms is critical toward ...

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart ...

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

ST. PAUL, Minn. & SAN DIEGO, Calif. -- St. Jude Medical, Inc., a global medical device company, today announced a new data analysis from the CHAMPION trial showing that heart failure (HF) patients ...

The appraisal committee considered evidence submitted by Boehringer Ingelheim, a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers ...